DK2739310T3 - Forbedrede fremgangsmåder og sammensætninger til modulering af OLFML3-medieret angiogenese - Google Patents

Forbedrede fremgangsmåder og sammensætninger til modulering af OLFML3-medieret angiogenese Download PDF

Info

Publication number
DK2739310T3
DK2739310T3 DK12741236.9T DK12741236T DK2739310T3 DK 2739310 T3 DK2739310 T3 DK 2739310T3 DK 12741236 T DK12741236 T DK 12741236T DK 2739310 T3 DK2739310 T3 DK 2739310T3
Authority
DK
Denmark
Prior art keywords
olfml3
antibody
cancer
cells
composition
Prior art date
Application number
DK12741236.9T
Other languages
English (en)
Inventor
Beat A Imhof
Marijana Miljkovic-Licina
Philippe Hammel
Original Assignee
Res Found Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev filed Critical Res Found Dev
Application granted granted Critical
Publication of DK2739310T3 publication Critical patent/DK2739310T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (15)

1. Sammensætning omfattende et antistof eller en nukleinsyre, der koder for antistoffet, hvor antistoffet genkender og binder til en aminosyresekvens defineret af (i) aminosyreposition 86-99 med SEQ ID NO: 1 eller (ii) aminosyrepo-sition 390-403 med SEQ ID NO:1 (menneskeligt Olfml3-protein) til anvendelse ved behandling af et individ med en angiogenisk tilstand, der er valgt blandt cancer eller okulær neovaskularisering.
2. Sammensætning til anvendelse ifølge krav 1, hvor antistoffet genkender aminosyreposition 86-99.
3. Sammensætning til anvendelse ifølge krav 1, hvor antistoffet genkender aminosyreposition 390-403.
4. Sammensætning til anvendelse ifølge krav 1, hvor den angiogeniske tilstand er en cancer.
5. Sammensætning til anvendelse ifølge krav 1 eller 4, hvor canceren er brystcancer, lungecancer, prostatacancer, æggestokcancer, hjernecancer, levercancer, livmoderhalskræft, kolorektal cancer, nyrecancer, hudcancer, hoved-og halscancer, knoglecancer, spiserørscancer, blærecancer, livmodercancer, lymfatisk cancer, mavecancer, pancreascancer, testikelcancer, lymfom eller leukæmi.
6. Sammensætning til anvendelse ifølge krav 1, hvor den angiogeniske tilstand er okulær neovaskularisering, især hvor den okulære neovaskularisering indbefatter makulær degeneration, aldersrelateret makulær degeneration (ARMD), afvisning af hornhindetransplantat, hornhindeneovaskularisering, præmaturitetsretinopati og diabetisk retinopati.
7. Sammensætning til anvendelse ifølge krav 1, hvor antistoffet inhiberer bindingen af menneske- eller muse-Olfml3-protein til BMP4-protein.
8. Sammensætning til anvendelse ifølge krav 1, hvor antistoffet er et monoklo-nalt antistof, et polyklonalt antistof, et kimært antistof, et affinitetsmodnet antistof, et humaniseret antistof, et humant antistof eller et antistoffragment.
9. Sammensætning til anvendelse ifølge krav 8, hvor antistoffet er et monoklo-nalt antistof.
10. Sammensætning til anvendelse ifølge krav 1, hvor antistoffet er et antistoffragment, der er valgt fra gruppen bestående af Fab, Fab', Fab'-SH, F(ab> og scFv.
11. Sammensætning til anvendelse ifølge krav 1, hvor antistoffet er fastgjort til et middel, der skal tilføres til en angiogenisk celle.
12. Sammensætning til anvendelse ifølge krav 11, hvor midlet er et cytotoksisk middel, en cytokin, et anti-angiogenisk middel, et kemoterapeutisk middel, et diagnostisk middel, et billeddannelsesmiddel, en radioisotop, et pro-apoptose-middel, et enzym, et hormon, en vækstfaktor, et peptid, et protein, et antibiotikum, et antistof eller et fragment deraf, et billeddannelsesmiddel, et antigen, en overlevelsesfaktor, et anti-apoptotisk middel, en hormonantagonist, et virus, et bakteriofag, en bakterie, et liposom, en mikropartikel, en magnetisk perle, en mikroindretning, en celle, en nukleinsyre eller en ekspressionsvektor.
13. Sammensætning til anvendelse ifølge krav 1, hvor sammensætningen endvidere omfatter en lipidbestanddel.
14. Sammensætning til anvendelse ifølge krav 13, hvor lipidbestanddelen danner et liposom.
15. Sammensætning til anvendelse ifølge krav 14, hvor lipidbestanddelen er 1,2-dioleoyl-sn-glycero-3-phosphatidylcholin (DOPC), ægge-phosphatidylcho-lin ("EPC"), dilauryloylphosphatidylcholin ("DLPC"), dimyristoylphospha-tidylcholin ("DMPC"), dipalmitoylphosphatidylcholin ("DPPC"), diste-aroylphosphatidylcholin ("DSPC"), 1 -myristoyl-2-palmitoylphosphatidylcholin ("MPPC"), 1-palmitoyl-2-myristoylphosphatidylcholin ("PMPC"), 1 -palmitoyl-2- stearoylphosphatidylcholin ("PSPC"), 1 -stearoyl-2-palmitoylphosphatidylcho-lin ("SPPC"), dimyristylphosphatidylcholin ("DMPC"), 1,2-distearoyl-sn-gly-cero-3-phosphocholin ("DAPC"), 1,2-diarachidoyl-sn-glycero-3-phosphocholin ("DMPC"), 1,2-dieicosenoyl-sn-glycero-3-phosphocholin ("DEPC"), palmito-yloeoylphosphatidylcholin ("POPC"), lysophosphatidylcholin, dilino-leoylphosphatidylcholin-distearoylphophatidylethanolamin ("DSPE"), dimy-ristoyl-phosphatidylethanolamin ("DMPE"), dipalmitoylphosphatidylethanola-min ("DPPE"), palmitoyloeoyl-phosphatidylethanolamin ("POPE"), lysop-hosphatidylethanolamin, phosphatidylserin, phosphatidylglycerol, dimy-ristoylphosphatidylserin ("DMPS"), dipalmitoylphosphatidylserin ("DPPS"), hjerne-phosphatidylserin ("BPS"), dilauryloylphosphatidylglycerol ("DLPG"), dimyristoylphosphatidylglycerol ("DMPG"), dipalmitoylphosphatidylglycerol ("DPPG"), distearoylphosphatidylglycerol ("DSPG"), dioleoylphosphatidylgly-cerol ("DOPG"), kolesterol eller polyethylenglycol (PEG).
DK12741236.9T 2011-08-05 2012-07-25 Forbedrede fremgangsmåder og sammensætninger til modulering af OLFML3-medieret angiogenese DK2739310T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161515669P 2011-08-05 2011-08-05
US201261664491P 2012-06-26 2012-06-26
PCT/US2012/048064 WO2013022599A1 (en) 2011-08-05 2012-07-25 Improved methods and compositions for modulation of olfml3 mediated angiogenesis

Publications (1)

Publication Number Publication Date
DK2739310T3 true DK2739310T3 (da) 2018-07-16

Family

ID=46599027

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12741236.9T DK2739310T3 (da) 2011-08-05 2012-07-25 Forbedrede fremgangsmåder og sammensætninger til modulering af OLFML3-medieret angiogenese

Country Status (7)

Country Link
US (4) US8663637B2 (da)
EP (1) EP2739310B1 (da)
AU (1) AU2012294814A1 (da)
CA (1) CA2842971C (da)
DK (1) DK2739310T3 (da)
HU (1) HUE039009T2 (da)
WO (1) WO2013022599A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8663637B2 (en) * 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis
WO2015054441A1 (en) * 2013-10-09 2015-04-16 Research Development Foundation Monoclonal olfml-3 antibodies and uses thereof
CN107056946A (zh) * 2016-12-28 2017-08-18 华南农业大学 一种抗二乙氧基硫代磷酸酯类有机磷农药的Fab抗体及制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4606855A (en) 1982-07-26 1986-08-19 Mex Research Associates C/O Leon Reimer Monoclonal antibody to digoxin
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3330160A1 (de) 1983-08-20 1985-03-07 Boehringer Ingelheim KG, 6507 Ingelheim Monoklonaler antikoerper mit hoher affinitaet zum digoxin
DE3342870A1 (de) 1983-11-26 1985-06-05 Boehringer Mannheim Gmbh, 6800 Mannheim Digitalis-antikoerper, verfahren zu ihrer herstellung und ihre verwendung zur therapie von digitalis-intoxikationen
US4767720A (en) 1985-08-29 1988-08-30 Hsc Research Development Corporation Antidigoxin antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5164296A (en) 1990-08-31 1992-11-17 University Of Maryland At Baltimore Assay methods involving ouabain
US5656434A (en) 1990-12-28 1997-08-12 Suntory Limited Monoclonal antibody against cardiac glycoside and utilization thereof
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5770376A (en) 1992-12-02 1998-06-23 Biomedical Sciences Research Laboratories, Inc. Method of diagnosing and treating myocardial infarction and hypertension
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5420253A (en) 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
ATE243745T1 (de) 1994-01-31 2003-07-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US6709873B1 (en) 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
US6861572B1 (en) 1997-11-14 2005-03-01 Origen Therapeutics, Inc. Production of proteins in eggs
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20030096955A1 (en) * 1998-09-01 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
US20020064528A1 (en) 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6753407B2 (en) 2000-08-15 2004-06-22 North Carolina State University Antimicrobial peptides isolated from fish
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US6891024B2 (en) 2001-05-24 2005-05-10 The Curators Of The University Of Missouri Monoclonal antibodies to Sarcocystis neurona and uses therefor
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
CA2496253C (en) 2002-07-19 2016-05-10 Beth Israel Deaconess Medical Center, Inc. Methods of diagnosing and treating pre-eclampsia or eclampsia
WO2004112566A2 (en) * 2003-06-25 2004-12-29 Quark Biotech, Inc. Diagnosis and treatment of nephropathy
US20110287088A1 (en) * 2008-12-03 2011-11-24 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US8663637B2 (en) * 2011-08-05 2014-03-04 Research Development Foundation Methods and compositions for modulation of Olfml3 mediated angiogenesis

Also Published As

Publication number Publication date
US20160333084A1 (en) 2016-11-17
CA2842971C (en) 2019-11-12
AU2012294814A1 (en) 2014-02-27
EP2739310B1 (en) 2018-04-18
EP2739310A1 (en) 2014-06-11
HUE039009T2 (hu) 2018-12-28
US9096662B2 (en) 2015-08-04
US20130034493A1 (en) 2013-02-07
WO2013022599A1 (en) 2013-02-14
US20140199237A1 (en) 2014-07-17
US20150299306A1 (en) 2015-10-22
CA2842971A1 (en) 2013-02-14
US8663637B2 (en) 2014-03-04

Similar Documents

Publication Publication Date Title
EP2513146B1 (en) Antibodies against ror1 capable of inducing cell death of cll
EP3191525B1 (en) Blocking monoclonal antibodies to agr2 and its receptor c4.4a
US20160333084A1 (en) Methods and compositions for modulation of olfml3 mediated angiogenesis
AU2014331923B2 (en) Monoclonal Olfml-3 antibodies and uses thereof
US20110287088A1 (en) Modulation of olfml-3 mediated angiogenesis
US20180214546A1 (en) Modulation of srpx2-mediated angiogenesis
US20210371508A1 (en) Nmes1 antibodies and methods of use thereof
US20210340232A1 (en) Monoclonal antibodies against human dickkopf3 and uses thereof
CN117085132A (zh) 阻断胸膜间皮细胞cd93的活性物质及应用